Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients

doi:10.12998/wjcc.v9.i36.11156

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 36

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3436)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

224

WORD

126

HTML

2267

Tables (1-4)

151

Sum=2768

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

233

Download

435

Sum=668

Dec 26, 2021 (publication date) through May 4, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Dec 26, 2021; 9(36): 11156-11164
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11156

Table 1 Clinical and metabolic characteristics of the three groups

Characteristics	NC	T2DM	DPN
n	39	49	47
Gender (M/F)	20/19	23/26	24/23
Age (yr)	52.31 ± 1.93	54.20 ± 1.58	58.87 ± 1.40
BMI (kg/m²)	24.04 ± 0.45	27.91 ± 0.55^a	26.67 ± 0.52^a
Diabetes duration (yr)	-	1.00 (0.20-4.50)	10.00 (4.00-15.00)^c
SBP (mmHg)	128 (119-133)	131 (118-146)^a	141 (126-153)^a
DBP (mmHg)	75.97 ± 0.89	85.96 ± 1.48^a	86.79 ± 1.73^a
FPG (mmoL/L)	5.31 (4.92-5.79)	9.02 (7.30-10.61)^a	8.09 (6.77-9.89)^a
HbA_1c (%)	5.50 ± 0.05	8.92 ± 0.29^a	8.06 ± 0.26^a
FCP (ng/mL)	1.65 (1.18-2.19)	1.24 (1.00-2.02)	1.31 (0.85-2.16)
FINS (uIU/mL)	6.87 (4.35-9.60)	5.85 (3.25-10.30)	6.84 (3.90-9.97)
HOMA-IR	1.49 (1.00-2.42)	2.42 (1.26-4.18)^a	2.59 (1.23-4.50)^a
TG (mmoL/L)	0.90 (0.62-1.24)	1.93 (1.32-3.87)^a	1.89 (1.12-2.75)^a
LDL (mmoL/L)	3.02 ± 0.13	3.07 ± 0.13	3.08 ± 0.17
HDL (mmoL/L)	1.36 ± 0.06	1.13 ± 0.04^a	1.25 ± 0.05^a
SCr (umoL/L)	50.33 ± 2.84	64.7 ± 2.01^a	63.56 ± 1.96^a
BUN (mmoL/L)	5.27 ± 0.25	3.41 ± 0.21	4.84 ± 0.15^c
UA (mmoL/L)	300.90 ± 10.80	309.79 ± 10.48	282.58 ± 11.74
eGFR (mL/min/1.73m²)	154.90 (122.90-214.60)	116.30 (101.40-140.30)^a	114.00 (98.16-130.00)^a
Sestrin2 (ng/mL)	9.10 (5.41,13.53)	14.58 (7.93-26.62)^a	9.86 (6.72-21.71)^c

^aP < 0.05 vs normal control group.

^cP < 0.05 vs type 2 diabetes mellitus group.

M: Male; F: Female; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; HbA_1c: Glycosylated hemoglobin A1_c; FCP: Fasting C peptide; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment of insulin resistance; TG: Triglyceride; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; Scr: Serum creatinine; BUN: Blood urea nitrogen; UA: Uric acid; eGFR: Estimated glomerular ﬁltration rate; NC: Normal control; T2DM: Type 2 diabetes mellitus; DPN: Diabetic peripheral neuropathy.

Table 2 Correlation analysis between Sestrin2 and clinical characteristics

Characteristics	Sestrin2
Characteristics	r value	P value
Age	0.088	0.312
DD	0.134	0.122
BMI	0.672	0.000^a
DBP	0.053	0.539
SBP	0.014	0.868
FPG	0.202	0.018^a
HbA1c	0.292	0.000^a
FCP	0.016	0.861
FINS	-0.008	0.927
HOMA-IR	0.115	0.183
TG	0.731	0.000^a
TC	0.485	0.621
LDL	0.088	0.309
HDL	0.051	0.559
SCr	0.206	0.016^a
BUN	0.094	0.281
UA	-0.002	0.980
eGFR	-0.230	0.007^a

^aP < 0.05.

DD: Diabetes duration; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin A1c; FCP: Fasting C peptide; TG: Triglyceride; TC: Total cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; SCr: Serum creatinine; BUN: Blood urea nitrogen; UA: Uric acid; eGFR: Estimated glomerular ﬁltration rate; FINS: Fasting insulin; HOMA-IR: Homeostasis model assessment of insulin resistance.

Table 3 Unstandardized and standardized β-coefficients for associations of Sestrin2 with clinical characteristics in multivariate analysis

Sestrin2	B	SE	β	t	P value	95%CI
BMI	1.130	0.197	0.422	5.732	0.000	0.740-1.521
HbA1c	0.477	0.406	0.095	1.174	0.242	-0.327-1.281
TG	3.323	0.541	0.443	6.146	0.000	2.253-4.392
FPG	-0.417	0.286	-0.115	-1.460	0.147	-0.982-0.148
SCr	0.003	0.068	0.005	0.050	0.960	-1.131-0.138
eGFR	-0.006	0.023	-0.025	-0.243	0.808	-0.051-0.040

BMI: Body mass index; HbA1c: Glycosylated hemoglobin A1c; TG: Triglyceride; FPG: Fasting plasma glucose; SCr: Serum creatinine; eGFR: estimated glomerular ﬁltration rate; CI: Confidence interval.

Table 4 Multivariate logistic analysis of risk factors for diabetic peripheral neuropathy

Risk factors	OR	95%CI	P value
Sestrin2	0.855	0.975-0.750	0.019
DD	1.411	1.695-1.175	0.000
HDL	0.041	0.880-0.002	0.041

DD: Diabetes duration; HDL: High-density lipoprotein; OR: Odds ratio; CI: Confidence interval.

Citation: Mao EW, Cheng XB, Li WC, Kan CX, Huang N, Wang HS, Hou NN, Sun XD. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients. World J Clin Cases 2021; 9(36): 11156-11164
URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11156.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11156